ADP-ribosylation inhibitors in treatment of diseases

Due to the growing interest in the basic biology of PARPs and ADP-ribosylation reactions, the expansion of understanding of the PARP family, and the growing clinical promise of PARP inhibitors as therapeutic agents, in Europe PARP meetings have been organized in Budapest (http://parp2019.hu/), the most recent one from 20 to 23 May 2019 (organized by Nicola Curtin, Daniela Corda, José Yelamos and Peter Bai). Next year, W. Lee Kraus, from UT Southwestern Medical Center, Susan Smith, from New York University, and Andreas Ladurner, from Ludwig-Maximilians-Universität, Munich, Germany, will organize the Cold Spring Harbor Laboratory meeting "PARPs and ADP-ribosylation," in New York (1-4 April 2020) and a new meeting will be organised in 2021 in Barcelona. These meetings highlight the latest advances of the PARP field and the field is moving towards with an immense velocity. Post-translational modifications, such as ADP-ribosyl transfer, are enzymatic reactions with a temporal switch, regulated by other enzymes reverting the modification: ADP-ribosyl transferases (ADPRTs) form either poly-ADP-ribose (PAR) polymers, or add only mono ADP-ribose (MAR) residue to the acceptor proteins.